A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus
Latest Information Update: 08 Apr 2025
At a glance
- Drugs CT-388 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Carmot Therapeutics
- 19 Nov 2024 Planned initiation date changed from 30 Oct 2024 to 30 Nov 2024.
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.
- 09 Oct 2024 Status changed from planning to not yet recruiting.